Bowen D - Search Results

1

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, Muus P, Te Boekhorst P, Sanz G, Del Cañizo C, Guerci-Bresler A, Nilsson L, Platzbecker U, Lübbert M, Quesnel B, Cazzola M, Ganser A, Bowen D, Schlegelberger B, Aul C, Knight R, Francis J, Fu T, Hellström-Lindberg E; MDS-004 Lenalidomide del5q Study Group. Fenaux P, et al. Among authors: bowen d. Blood. 2011 Oct 6;118(14):3765-76. doi: 10.1182/blood-2011-01-330126. Epub 2011 Jul 13. Blood. 2011. PMID: 21753188 Free article. Clinical Trial.

2

Pathogenesis, etiology and epidemiology of myelodysplastic syndromes.

Aul C, Bowen DT, Yoshida Y. Aul C, et al. Among authors: bowen dt. Haematologica. 1998 Jan;83(1):71-86. Haematologica. 1998. PMID: 9542325 Review.

3

Cytogenetic abnormalities in the myelodysplastic syndromes and occupational or environmental exposure.

West RR, Stafford DA, White AD, Bowen DT, Padua RA. West RR, et al. Among authors: bowen dt. Blood. 2000 Mar 15;95(6):2093-7. Blood. 2000. PMID: 10706879 Free article.

4

Best supportive care for the anaemia of myelodysplasia: inclusion of recombinant erythropoietin therapy?

Bowen DT, Hellstrom-Lindberg E. Bowen DT, et al. Leuk Res. 2001 Jan;25(1):19-21. doi: 10.1016/s0145-2126(00)00100-4. Leuk Res. 2001. PMID: 11137556 No abstract available.

5

Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes.

Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, Parker J; UK MDS Guidelines Group. Bowen D, et al. Br J Haematol. 2003 Jan;120(2):187-200. doi: 10.1046/j.1365-2141.2003.03907.x. Br J Haematol. 2003. PMID: 12542475 Free article. No abstract available.

6

A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia.

Killick SB, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC, Bowen DT, Marsh JC. Killick SB, et al. Among authors: bowen dt. Br J Haematol. 2003 Feb;120(4):679-84. doi: 10.1046/j.1365-2141.2003.04136.x. Br J Haematol. 2003. PMID: 12588356 Free article. Clinical Trial.

7

No increase in age-specific incidence of myelodysplastic syndromes.

Germing U, Strupp C, Kündgen A, Bowen D, Aul C, Haas R, Gattermann N. Germing U, et al. Among authors: bowen d. Haematologica. 2004 Aug;89(8):905-10. Haematologica. 2004. PMID: 15339672

8

Thalidomide therapy for low-risk Myelodysplasia.

Bowen D, MacIlwaine L, Cavanagh J, Killick S, Culligan D, Thomson E, Mufti G. Bowen D, et al. Leuk Res. 2005 Feb;29(2):235-6. doi: 10.1016/j.leukres.2004.05.017. Leuk Res. 2005. PMID: 15607375 No abstract available.

9

Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.

Vey N, Bosly A, Guerci A, Feremans W, Dombret H, Dreyfus F, Bowen D, Burnett A, Dennis M, Ribrag V, Casadevall N, Legros L, Fenaux P. Vey N, et al. Among authors: bowen d. J Clin Oncol. 2006 Jun 1;24(16):2465-71. doi: 10.1200/JCO.2005.03.9503. Epub 2006 May 1. J Clin Oncol. 2006. PMID: 16651646 Clinical Trial.

10

Time-dependent prognostic scoring system for myelodysplastic syndromes has significant limitations that may influence its reproducibility and practical application.

Bowen DT, Fenaux P, Hellstrom-Lindberg E, de Witte T. Bowen DT, et al. J Clin Oncol. 2008 Mar 1;26(7):1180; author reply 1181-2. doi: 10.1200/JCO.2007.15.2926. J Clin Oncol. 2008. PMID: 18309958 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,483 results

Search Page